Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Identification of anticancer drugs to radiosensitise BRAFwild- type and mutant colorectal cancer
Carter R. et al, (2019), Cancer Biology and Medicine, 16, 234 - 246
Defining the Functional Role of NaV1.7 in Human Nociception.
McDermott LA. et al, (2019), Neuron
Microglial inflammation and phagocytosis in Alzheimer's disease: potential therapeutic targets.
Nizami S. et al, (2019), Br J Pharmacol
HUMAN MESOTHELIOMA CELL LINES DEVELOPED FROM MALIGNANT PLEURAL EFFUSIONS AS TOOLS TO DEVELOP NOVEL THERAPIES AND GUIDE PERSONALISED MEDICINE
Kanellakis NI. et al, (2018), THORAX, 73, A81 - A82
A novel high-content imaging-based technique for measuring binding of Dickkopf-1 to low-density lipoprotein receptor-related protein 6.
Priestley RS. et al, (2018), J Pharmacol Toxicol Methods